DWA
CTIC

Dorsey Wright & Associates’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Dorsey Wright & Associates’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$48K Buy
+8,100
New +$41.5K 0.01% 149

Other funds holding CTIC

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Dorsey Wright & Associates's CTIC Position: Q2 2022 in Review

Dorsey Wright & Associates opened a new position in CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2022: 8,100 shares worth $48K. The stake represents 0.01% of the portfolio and ranks #149 among its holdings.

119 funds tracked by Wall St. Rank hold CTIC as of Q2 2022.

  • Dorsey Wright & Associates held 8,100 shares of CTI BioPharma Corp. (DE) Common Stock worth $48K as of Q2 2022.
  • CTI BioPharma Corp. (DE) Common Stock was a new Dorsey Wright & Associates position in Q2 2022.
  • CTI BioPharma Corp. (DE) Common Stock made up 0.01% of Dorsey Wright & Associates's portfolio in Q2 2022, its #149 holding.
  • 119 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2022.

Based on Dorsey Wright & Associates's 13F filing for Q2 2022, filed 20 Jul 2022.